

HDFC Life Insurance



Estimate change TP change Rating change

Bloomberg	HDFCLIFE IN
Equity Shares (m)	2152
M.Cap.(INRb)/(USDb)	1143.3 / 14
52-Week Range (INR)	621 / 458
1, 6, 12 Rel. Per (%)	3/-1/-7
12M Avg Val (INR M)	2341

Financials & Valuations (INR b)

FY23	FY24E	FY25E
567.6	682.4	826.2
13.6	13.6	16.4
13.6	16.2	19.1
20.4	14.0	20.0
38.0	11.0	21.2
25.2	19.8	21.1
27.6	28.5	29.4
19.9	19.5	19.1
2.4	2.9	3.4
36.7	42.2	52.7
184	219	261
2.9	2.4	2.0
17.6	15.0	12.4
	567.6 13.6 13.6 20.4 38.0 25.2 27.6 19.9 2.4 36.7 184	567.6 682.4 13.6 13.6 13.6 16.2 20.4 14.0 38.0 11.0 25.2 19.8 27.6 28.5 19.9 19.5 2.4 2.9 36.7 42.2 184 219 2.9 2.4

Shareholding pattern (%)

As On	Mar-23	Dec-22	Mar-22
Promoter	50.3	50.3	51.5
DII	6.6	6.2	7.8
FII	29.9	30.2	26.3
Others	13.2	13.3	14.3

FII Includes depository receipts

CMP: INR532 TP: INR610 (+14%) Neutral

Growth outlook remains healthy; VNB margin improves

Persistency ratios inch up

- HDFC Life Insurance (HDFCLIFE) posted a healthy 4QFY23 performance with a strong beat in both APE and VNB. Premium growth was healthy driven by both renewal premium (+26% YoY) and new business premium (+47% YoY).
- APE rose 69% YoY to INR51.6b (26% beat) in 4QFY23 propelled by Non-PAR, PAR and Group businesses. Demand for ULIP was soft due to volatile capital markets while trend in protection improved QoQ.
- VNB too rose 69% YoY (26% beat) with margin expanding 240bp QoQ to 29.3%. Embedded Value (EV) grew 5% QoQ to INR395b during the quarter.
- We estimate HDFCLIFE to deliver ~20% VNB CAGR over FY23-25 and margin would improve to ~29% by FY25. Reiterate Neutral with a TP of INR610 (premised on 2.4x Sep'24E EV).

Protection trends improving; operating RoEV at 19.7% in FY23E

- HDFCLIFE's total premium rose 36% YoY to INR196b (8% beat) within which new business premium grew 47% YoY while renewal premium rose 26% YoY, aided by higher persistency across cohorts. PAT was flat YoY at INR3.6b (12% miss) in 4QFY23. The FY23 PAT was up 13% YoY to INR13.6b.
- Total APE grew 69% YoY to INR51.6b (26% beat) in 4QFY23 with individual APE rising 75% YoY. Within total APE, Non-PAR spiked 157% YoY in 4QFY23 (driven by higher demand due to budgetary changes) while Group/PAR segment rose 104%/34% YoY. Protection was up 19% YoY and is witnessing healthy sequential trends. ULIP segment declined 1% YoY in 4QFY23.
- VNB grew 69% YoY to INR15.1b (26% beat) with FY23 VNB at INR36.7b (+37% YoY). VNB margin improved ~240bp QoQ to 29.3%, driven by an optimal business mix. VNB margin stood at 27.6% over FY23.
- On the distribution front, the share of banca moderated to 51% while agency channel constituted 23% share. This increase was at the cost of direct channel as it continues to face headwind in the form of heightened competition; its share moderated to 10% in 4QFY23 from 19% in 4QFY22.
- Operating return on EV came in at 19.7%. Total EV grew 5% QoQ to INR395b. Total AUM increased 17% YoY to INR2.4t while solvency ratio stood at 203% (600bp QoQ decline).

Highlights from the management commentary

- Protection and annuity to be the key growth drivers that will see a healthy trend in FY24E on adjusted base (INR10b due to a bump up in Mar'23).
- Counter share at HDFC Bank should start inching up going ahead (70%). It expects to see a sequential growth on a sustained basis for the same.
- For FY24E, management is confident of VNB growth to be in line with APE growth leading to stable VNB margin. While over the longer term, there will be margin expansion.

Nitin Aggarwal - Research Analyst (Nitin.Aggarwal@MotilalOswal.com)

Research Analyst: Yash Agarwal (Yash.Agarwal@motilaloswal.com) | Prayesh Jain (Prayesh.Jain@MotilalOswal.com)

Valuation and view

HDFCLIFE remains focused on maintaining a balanced product mix, with an emphasis on product innovation and superior customer service. Non-PAR/ Annuity are likely to witness a steady growth while retail protection is reporting a gradual recovery that will aid the overall APE growth. Credit life will continue to witness healthy traction as the momentum in disbursements across lending institutions remains strong. Persistency trend improved across all cohorts that will keep the renewal premium growth healthy. We estimate HDFCLIFE to deliver ~20% VNB CAGR over FY23-25 and margin to improve to ~29% by FY25. Reiterate Neutral with a TP of INR610 (premised on 2.4x Sep'24E EV).

Quarterly performance												(INR b)
Delieu helderle A /e /IND h)	FY22 FY23						FY22	FY23	FY23E	V/a aat		
Policy holder's A/c (INR b)	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	FYZZ	F123	4Q	V/s est.
First year premium	12.9	20.8	21.2	25.7	17.1	24.2	27.2	44.7	80.5	113.2	37.0	20.8
Growth (%)	25.8%	24.0%	19.4%	7.8%	32.9%	16.6%	28.8%	73.5%	17.4%	40.6%	43.7%	
Renewal premium	38.9	50.3	55.4	73.4	51.0	69.1	71.9	92.5	218.1	284.5	90.3	2.5
Growth (%)	20.1%	16.8%	21.1%	15.6%	31.1%	37.2%	29.7%	26.1%	18.0%	30.4%	22.9%	
Single premium	24.8	45.2	46.0	45.1	32.4	39.5	46.6	59.0	161.0	177.6	53.7	10.0
Growth (%)	54.9%	7.7%	40.2%	8.0%	30.6%	-12.5%	1.5%	31.1%	21.5%	10.3%	19.1%	
Gross premium income	76.6	116.3	122.5	144.2	100.5	132.8	145.8	196.3	459.6	575.3	180.9	8.5
Growth (%)	30.6%	14.2%	27.3%	11.7%	31.3%	14.2%	18.9%	36.1%	19.1%	25.2%	25.4%	
PAT	3.0	2.7	2.7	3.6	3.6	3.3	3.2	3.6	12.1	13.6	4.1	-11.7
Growth (%)	-33.0%	-15.9%	3.3%	12.4%	19.1%	19.0%	15.2%	0.3%	-11.2%	12.6%	13.6%	
Key metrics (INR b)												
New business APE	15.6	25.5	26.0	30.5	19.0	30.1	32.6	51.6	96.6	133.4	41.0	25.8
Growth (%)	30.3	19.4	20.4	5.8	22.0	18.0	25.5	69.3	18.1	38.0	34.6	
VNB	4.1	6.8	6.9	9.0	5.1	7.8	8.8	15.1	26.7	36.7	12.0	25.8
Growth (%)	40.2	23.9	21.8	15.2	25.0	14.7	26.1	68.8	22.4	37.4	34.2	
AUM (INR b)	1,813	1,912	1,947	2,042	2,001	2,249	2,338	2,388	2,042	2,388	2,506	-4.7
Growth (%)	29.5	27.0	17.6	17.4	10.4	17.6	20.1	17.0	17.4	17.0	22.7	
Key Ratios (%)												
VNB Margins (%)	26.2	26.6	26.7	29.4	26.8	25.8	26.8	29.3	27.4	27.6	29.3	1
Solvency ratio (%)	203.0	190.0	190.0	176.0	178.0	210.0	209.0	203.0	175.6	203.3	205.7	-271

Quarterly snapshot					I									
			21				22				23			ge (%)
Not an automation to a succession	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	YoY	QoQ
Net premium income First year prem	57.2 10.2	100.5 16.8	94.9 17.7	128.7 23.9	75.4 12.9	114.4 20.8	121.2 21.2	142.9 25.7	98.5 17.1	131.1 24.2	143.8 27.2	194.3 44.7	36 73	35 64
Renewal prem	32.4	43.1	45.8	63.5	38.9	50.3	55.4	73.4	51.0	69.1	71.9	92.5	26	29
Single prem	16.0	42.0	32.8	41.7	24.8	45.2	46.0	75.4 45.1	32.4	39.5	46.6	59.0	31	29 27
Investment income	87.5	63.2	115.9	60.2	69.6	88.7	19.8	14.0	-33.0	97.8	49.3	11.9	-15	-76
Total income (A)	145.1	164.1	211.3	191.9	146.0	204.8	142.2	160.5	66.1	229.7	196.9	214.3	33	9
Commission paid	2.4	4.2	4.5	6.0	3.0	5.1	5.1	6.2	4.0	6.7	6.8	10.9	75	61
Operating expense	6.7	11.0	13.1	15.1	9.5	13.5	15.0	18.1	15.6	18.4	21.2	29.2	61	38
Total comm. & Opex	9.1	15.3	17.6	21.1	12.5	18.6	20.1	24.3	19.6	25.1	28.0	40.1	65	43
Total Expenses (B)	142.0	161.7	207.7	185.7	146.6	202.5	139.4	152.5	62.8	226.0	194.0	205.1	35	6
PBT	2.8	1.6	3.2	6.2	0.6	1.8	2.0	7.1	2.2	2.7	2.0	8.2	16	314
Tax	0.3	0.2	0.4	1.8	0.0	0.1	0.2	1.5	0.1	0.2	-1.3	2.5	62	-291
Surplus/(Deficit)	2.5	1.4	2.7	4.3	0.6	1.6	1.8	5.5	2.1	2.5	3.3	5.7	4	73
Shareholder A/c														
Trf from Policyholder	3.5	2.2	1.4	2.9	1.2	2.0	1.8	5.0	2.5	2.2	4.2	5.8	17	40
Investment Income	1.0	1.4	1.4	2.7	2.6	2.0	1.8	1.5	1.2	1.6	2.4	2.0	33	-20
Total income	4.4	3.5	2.8	5.6	3.8	4.1	3.6	6.5	3.7	3.8	6.6	8.4	30	28
PBT	4.5	3.3	2.7	3.1	3.1	2.8	2.8	3.2	3.6	3.3	3.1	2.7	-16	-14
Tax	0.0	0.0	0.0	-0.1	0.0	0.0	0.0	-0.4	0.0	0.0	0.0	-0.9	147	8,970
PAT	4.5	3.3	2.6	3.2	3.0	2.7	2.7	3.6	3.6	3.3	3.2	3.6	0	14
Individual APE														
ULIP	2.9	3.6	4.2	6.4	3.5	5.4	5.6	6.7	3.9	4.8	5.8	7.2	7	25
PAR	3.2	6.1	7.0	7.9	3.8	6.5	6.5	7.8	4.6	8.1	7.2	10.8	40	51
Term	1.2	1.4	0.7	1.7	1.0	1.4	0.9	1.6	0.8	0.9	1.1	1.8	16	64
Non Par savings	3.0	5.5	5.5	8.1	4.2	6.8	7.4	8.6	5.4	9.8	11.6	24.5	186	111
Annuity	0.5	0.9	0.9	1.2	0.7	1.1	1.1	1.3	0.9	1.5	1.7	1.6	22	-5
Total individual APE	10.7	17.6	18.3	24.6	13.1	21.2	21.5	25.9	15.5	25.6	27.6	45.3	75	64
Total APE	12.0	21.4	21.6	28.8	15.6	25.5	26.0	30.5	19.0	30.1	32.6	51.6	69	58
APE (% of total)														
ULIP	27.0	20.6	23.0	25.9	27.0	25.4	26.0	26.0	25.0	18.6	21.0	16.0	-1,004	-504
PAR	30.0	34.8	38.1	32.1	29.0	30.6	30.0	30.0	30.0	31.6	26.0	24.0	-604	-206
Term	11.0	7.8	3.9	7.0	8.0	6.4	4.4	6.0	5.0	3.4	4.0	4.0	-200	0
Non Par savings	28.0	31.2	30.0	32.9	32.0	32.0	34.6	33.0	35.0	38.2	42.0	54.1	2,111	1,213
Distribution mix (%)														
Bancassurance	59.0	60.6	67.7	57.2	56.0	62.5	62.6	61.0	56.0	57.6	62.0	51.4	-956	-1,053
Individual agents	12.0	13.6	10.4	14.9	15.0	11.8	15.6	14.0	16.0	19.2	18.0	23.0	904	504
Direct	24.0	19.2	15.9	19.0	23.0	19.8	15.8	19.0	22.0	14.0	12.0	10.0	-904	-206
Broker	5.0	6.6	6.0	8.9	6.0	6.0	6.0	6.0	7.0	8.6	10.5	14.0	804	355
Key Ratios (%)														
Operating ratios		4.0		4.6	2.0			4.0	2.0	- 4			426	0.4
Commission (unwtd)		4.2	4.7	4.6	3.9	4.4	4.1	4.3	3.9	5.1	4.8	5.7	136	91
Opex (unwtd)	11.5	10.9	13.7	11.8	12.5	11.7	12.4	12.6	14.9	13.8	14.5	15.0	240	50
Total Cost Solvency ratio	15.5 190	15.0 203	18.2 202	16.3 201	16.4 203	16.0 190	16.4 190	16.8 176	18.8 178	19.0 210	19.3 209	20.5 203	370 2,700	120 -600
Profitability ratios	190	203	202	201	203	190	190	176	1/6	210	209	203	2,700	-600
VNB margins	24.3	25.6	26.4	27.0	26.2	26.6	26.7	29.4	26.8	25.8	26.8	29.3	-8	243
ROE	25.0	21.0	18.4	17.6	14.1	13.5	13.0	10.1	9.5	12.4	11.9	11.9	180	0
Op. ROEV	15.8	17.6	18.3	18.5	14.4	16.1	16.2	16.6	16.5	17.7	17.5	19.7	310	220
Persistency ratios	15.0	17.0	10.5	10.5	14.4	10.1	10.2	10.0	10.5	17.7	17.5	15.7	310	220
13th Month	87.0	88.0	89.0	90.0	90.0	86.0	87.0	87.5	93.0	87.0	87.0	87.5	0	50
25th Month	80.8	79.0	80.0	81.0	82.0	76.0	77.0	78.8	86.0	77.0	78.0	78.7	-10	70
37th Month	69.5	69.0	69.0	71.0	73.0	66.0	67.0	67.5	80.0	70.0	71.0	72.4	490	140
49th Month	64.9	66.0	67.0	67.0	67.0	63.0	63.0	63.2	72.0	63.0	64.0	64.0	80	0
61st Month	54.4	53.0	53.0	53.0	53.0	52.0	53.0	54.0	58.0	51.0	52.0	52.3	-170	30
Key Metrics (INR b)	31.4	33.0	33.0	33.0	33.0	32.0	55.0	3 1.0	33.0	31.0	32.0	32.3	1,0	30
VNB	2.9	5.5	5.7	7.8	4.1	6.8	6.9	9.0	5.1	7.8	8.8	15.1	69	73
EV	225.8	233.3	250.5	266.2	273.3	287.0	295.4	329.6	297.1	360.2	377.0	395.3	20	5
EVOP	7.7	9.8	10.3	10.5	10.3	13.2	12.9	14.2	11.7	13.8	16.8	22.5	58	34
AUM	1,400	1,506	1,656	1,738	1,813	1,912	1,947	2,042	2,001	2,249	2,338	2,388	17	2
Equity portion (%)		33	36	36	37	38	36	37	35	32	32	30	-700	-200
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1		\		- D - 51			I a de la calif	! - f	-1	4 .	3 11			

Note: a) Persistency ratios, RoE, and operating RoEV are on a cumulative basis for six, nine, and 12 months



Highlights from the management commentary **VNB**

- For FY24E, management is confident of VNB growth to be in line with APE growth leading to stable VNB margin. While over the longer term, there will be margin expansion as the share of HDFC Bank increases and there exists a lot of optionality from new products that could come through under new regulation and also from the Gift City.
- VNB will be primarily driven by APE growth. Margin accretion will come from nuances of product changes, fructification of investments in partnerships with banks over the past few quarters, efficiencies from technology and human resource costs spent in the recent past and higher share of longer-term product sale with protection growth. These factors will be balanced by investments in technology and partners.
- Intense competition was seen in Mar'23 with extreme pricing in the Non-PAR products but HDFCLIFE did not participate in the same. No major change in product level margins was seen.

EV

- In spite of the increase in new business strain, EV saw strong growth as there was a 27% growth in back book surplus.
- Interest rate curve has been higher that will lead to better unwind rate in FY24.

APE growth

- The proposition of long-term products continued to remain strong even on post-tax basis. In Mar'23, below INR0.5 policies grew 50%. Post-ULIP regulation, the share of ULIPs has gone up indicating decoupling between tax rate of products and APE growth of those products; for HNIs, tax has not been a driver.
- Protection and annuity will be key drivers going ahead and will see a strong growth in FY24E on an adjusted base of FY23 (INR10b adjustment for bump up in Mar'23).
- Yes Bank, Bandhan Bank and other partners have seen strong growth and management expects growth to sustain for these partners. HDFC Bank will provide an uptick, leading to a growth faster than the industry.
- The business was more granular 4-5 years ago. Hence, it is going to increase the number of policies.

Distribution

- Banca grew 25% based on Individual APE. Expect higher growth going ahead with HDFC Bank as well as other banks opening more and more branches.
- Agency channel has seen a five-year CAGR of 34% and will look to expand in new territories especially with the acquired entity.

Subsidiaries

- Pension subsidiary doubled its AUM in 1.5 years to INR340b.
- HDFC International received approval to set up a branch in Gift City; it will commence operations from 1QFY24.

Protection

- Total protection share has increased to 29% in FY23 from 24% in FY22, with a 20% growth driven by credit life (that was at 50% among 360+ partners). Going ahead, management expects retail protection to see strong growth.
- Growth in protection has been strong across all channels (most noteworthy being banca channel) and beyond the top 10 cities as well.
- The management was more enthused by growth opportunity for protection in HDFC Bank channel with products such as RoP.
- Credit protection was well spread with share of MFIs being at one-third and HDFC Bank being slightly less than one-third.
- Share of RoP rose to 20% with increase in business from tier 2 and tier 3 cities.
- Reinsurers are getting active and are looking to participate in the growth.

Annuity

- APE grew 59% in Annuity, which maintained its market share in the segment. Annuity rose 18% on NBP basis v/s 2% for the industry.
- There was a fairly frequent re-pricing in the market given the interest rate volatility. It will be able to maintain margins at a level higher than the companylevel margins.
- Pension category will revive under the new EOM regulations that will act as a feeder for growth for the annuity business.

New regulations

- Management is enthused about new EOM regulation; higher allowances in renewal will help improve persistency. Regulator is looking to move towards longer-term products wherein HDFCLIFE has a large market share.
- Impact of regulation changes has been favorable for HDFCLIFE and in each of the past disruptions, with the company delivering 1.5x- 2x premium growth v/s the industry.
- Share of high ticket (INR0.5m+ premium) was at 12-14% for FY23, while in 4QFY23 it was at 35%. As compared to actual growth of 27%, normalized growth was at 16%. Large share of the jump came in the second week of Mar'23 and the delta was of INR10b.
- Composite license Management is hopeful that the bill will get passed post which regulator will have to form regulations around it. HDFCLIFE does not want to redistribute the pie and will compare between life and health products with innovation.

HDFC Bank – HDFC Ltd merger

- Uncertainty removed, looking forward to collaborate with the parent especially with robust branch expansion.
- With a major expansion in tier 2 and tier 3 cities, different mortality assumptions will be needed for this cohort.
- Counter share at HDFC Bank should start inching up going ahead as per the communication with HDFC Bank. In various platforms both entities have mentioned about wallet share being increased to 70%. Expect to see sequential growth on a sustained basis for the same.

No concrete discussions have been done yet on fresh issue v/s secondary, but probability of secondary transaction growth is better. Aberdeen has a last 1.6% stake and the sale should materialize over the next 1-2 months.

Costs


Increased investment in technology will continue. INR1b each will be spent in FY24-25 for project Inspire; INR0.5b has been spent so far. These costs can be easily absorbed within the new EOM regulations.

Others

- Niraj Shah has been elevated to the Board as the ED and CFO.
- Persistency 61st month is lower because of the merger. Other cohorts continue to see strong growth and should be sustainable.


Key exhibits

Exhibit 1: Share of Non-PAR savings inched up to 54% of Individual APE but expected to normalize




Source: MOFSL, Company

Exhibit 2: Share of Non-PAR Savings/Annuity/Protection at 46%/3%/10% of total APE, respectively




Source: MOFSL, Company

Exhibit 3: Persistency ratio remained healthy across cohorts



Source: MOFSL, Company

Exhibit 4: Share of banca moderated in 4QFY23



Source: MOFSL, Company

Exhibit 5: Operating RoEV healthy at 19.7% with EV up 5% QoQ





Exhibit 6: VNB margin improved to 29.3% in 4QFY23; stood at 27.6% over FY23




Source: MOFSL, Company Source: MOFSL, Company

Valuation and view

- HDFCLIFE maintained market leadership as a top 3 life insurer in the industry with an individual APE-based market share of ~16.0% for FY23 among private insurers (v/s 8.0% in FY10).
- Product innovation has been a key differentiator and played a critical role in driving business growth. Several of the company's savings products – such as Sanchay Plus and Sanchay-PAR Advantage – have seen strong traction.
- Non-PAR/Annuity businesses are likely to witness healthy trends. Protection remains a long-term structural story, and the management will continue to leverage this opportunity on a prudent basis.
- We expect the share of high-margin products (Annuity, Non-PAR, and Protection) to remain steady, driving a steady VNB margin. We expect VNB margin of ~29% by FY25.
- HDFCLIFE has delivered strong return ratios in the past few years, which should remain robust, driven by: a) healthy new business margin, b) a balanced product mix, c) quality underwriting, and d) robust persistency ratios.
- Retain neutral with a TP of INR610: HDFCLIFE remains focused on maintaining a balanced product mix, with an emphasis on product innovation and superior customer service. Non-PAR/ Annuity are likely to witness a steady growth while retail protection is reporting a gradual recovery that will aid the overall APE growth. Credit life will continue to witness healthy traction as the momentum in disbursements across lending institutions remains strong. Persistency trend improved across all cohorts that will keep the renewal premium growth healthy. We estimate HDFCLIFE to deliver ~20% VNB CAGR over FY23-25 and margin to improve to ~29% by FY25. Reiterate Neutral with a TP of INR610 (premised on 2.4x Sep'24E EV).


Story in charts

Exhibit 7: Net premium income grew ~37% YoY led by healthy growth in new business and renewal premium




Source: MOFSL, Company

Exhibit 8: Proportion of premium trends among first year, single and renewal premiums




Source: MOFSL, Company

Exhibit 9: Trends in PAT, existing business surplus, and new business strain




Source: MOFSL, Company

Exhibit 10: Trends in underwriting profit and shareholders' surplus




Source: MOFSL, Company

Exhibit 11: Persistency trends improved across cohorts



Source: MOFSL, Company

Exhibit 12: Solvency ratio stood at 203% in 4QFY23



Source: MOFSL, Company

Financials and valuations

Technical account (INR b)	FY19	FY20	FY21	FY22	FY23	FY24E	FY25E
Gross Premiums	291.9	327.1	385.8	459.6	575.3	689.5	834.9
Reinsurance Ceded	(2.6)	(4.8)	(4.6)	(5.7)	(7.7)	(7.2)	(8.7)
Net Premiums	289.2	322.2	381.2	454.0	567.6	682.4	826.2
Income from Investments	90.3	(33.1)	326.8	192.2	126.0	226.6	260.2
Other Income	4.8	3.5	4.4	7.5	13.4	9.4	10.7
Total income (A)	384.4	292.6	712.4	653.6	707.1	918.4	1,097.1
Commission	11.2	14.9	17.1	19.4	28.9	31.0	37.9
Operating expenses	38.1	42.7	45.9	56.1	84.4	77.9	93.4
Total commission and opex	49.3	57.6	63.0	75.5	113.2	108.9	131.2
Benefits Paid (Net)	139.9	190.2	225.7	318.6	388.7	407.0	489.2
Change in reserves	175.1	24.4	408.3	246.8	185.9	388.2	459.2
Total expenses (B)	365.2	277.9	695.1	638.4	688.1	900.3	1,074.8
(A) - (B)	19.2	14.7	17.3	15.1	18.9	18.0	22.3
Tax (Inc. GST)	5.7	5.0	6.3	5.5	5.3	4.4	5.9
Surplus / Deficit	13.5	9.7	11.0	9.6	13.6	13.6	16.4
Shareholder's a/c (INR b)	FY19	FY20	FY21	FY22	FY23	FY24E	FY25E
Transfer from technical a/c	12.1	11.9	9.9	10.1	14.7	15.0	17.8
Income From Investments	4.1	4.4	6.5	7.9	7.2	4.5	5.2
Total Income	16.4	16.5	16.4	18.0	22.5	20.1	23.6
Other expenses	0.3	0.3	0.6	0.8	1.2	1.4	1.5
Contribution to technical a/c	3.1	1.0	2.6	5.7	8.8	2.4	2.7
Total Expenses	3.5	3.4	2.8	6.2	9.8	3.7	4.2
PBT	12.9	13.1	13.5	11.8	12.7	16.4	19.4
Tax	(0.1)	(0.2)	0.1	0.3	0.9	(0.2)	(0.3)
PAT	12.8	13.0	13.6	12.1	13.6	16.2	19.1
Growth	15%	1%	5%	-11%	13%	19%	18%
<u></u>	13/0	170	370	22/0	1370	23/0	10/0
Premium (INR b) & growth (%)	FY19	FY20	FY21	FY22	FY23	FY24E	FY25E
NBP - unweighted	149.7	172.4	201.1	241.5	290.9	331.6	397.9
NBP - wrp	60.5	71.6	81.8	96.6	133.4	148.0	179.4
Renewal premium	142.1	154.7	184.8	218.1	284.5	357.9	437.0
Total premium - unweighted	291.9	327.1	385.8	459.6	575.3	689.5	834.9
NBP growth - unweighted	31.9%	15.1%	16.6%	20.1%	20.4%	14.0%	20.0%
NBP growth - wrp	12.0%	18.4%	14.2%	18.1%	38.0%	11.0%	21.2%
Renewal premium growth	16.4%	8.8%	19.4%	18.0%	30.4%	25.8%	22.1%
Tot. premium growth - unweighted	23.9%	12.1%	18.0%	19.1%	25.2%	19.8%	21.1%
Premium mix (%)	FY19	FY20	FY21	FY22	FY23	FY24E	FY25E
New business - un weighted							
- Individual mix	51.1%	48.8%	49.9%	48.0%	65.0%	67.0%	66.0%
- Group mix	48.9%	51.2%	50.1%	52.0%	35.0%	33.0%	34.0%
New business mix - WRP							
- Participating	14.4%	15.9%	28.8%	25.2%	25.7%	25.6%	25.6%
- Non-participating	38.5%	59.5%	49.9%	51.7%	44.6%	43.9%	42.7%
- ULIPs	47.1%	24.5%	21.3%	23.1%	29.8%	30.5%	31.7%
Total premium mix - un weighted	77.1/0	27.3/0	21.3/0	25.1/0	25.070	30.370	31.770
- Participating	20.0%	18.5%	19.8%	19.7%	40.0%	40.0%	40.0%
- Non-participating	41.2%	47.3%	51.0%	54.1%	12.8%	12.8%	12.8%
- ULIPs	38.8%	34.2%	29.1%	26.2%	47.2%	47.2%	47.2%
- OLIF3	30.0/0	34.270	23.170	20.270	41.2/0	47.270	47.270
Indi premium sourcing mix (%)	FY19	FY20	FY21	FY22	FY23	FY24E	FY25E
Individual agents	13.8%	13.3%	12.3%	13.2%	17.0%	18.0%	19.0%
marriada agenta	13.070						
Cornorate agents-Ranks	16 7%	/11 Q0/	/IC Q0/	/// 50/-	// 6 60/.		
Corporate agents-Banks	46.7%	41.8%	45.8%	44.5%	46.6%	46.5%	44.9%
Corporate agents-Banks Direct business Others	46.7% 31.8% 7.8%	41.8% 35.0% 9.9%	45.8% 32.9% 9.0%	32.9% 9.4%	29.0% 7.4%	28.0% 7.5%	28.5% 7.6%

Financials and valuations

Balance sheet (INR b)	FY19	FY20	FY21	FY22	FY23	FY24E	FY25E
Sources of Fund							
Share Capital	20.2	20.2	20.2	21.2	21.5	21.5	21.5
Reserves And Surplus	36.4	49.7	64.1	132.9	108.1	119.4	132.9
Shareholders' Fund	56.6	68.0	86.4	154.9	129.9	141.1	154.6
Policy Liabilities	536.7	652.7	855.2	1,043.4	1,432.7	1,636.7	2,013.5
Prov. for Linked Liab.	605.2	508.4	709.6	765.2	753.8	940.9	1,054.7
Funds For Future App.	39.5	42.2	47.9	50.4	50.5	60.0	71.4
Current liabilities & prov.	51.2	49.8	65.2	62.3	81.1	105.4	137.0
Total	1,300.3	1,321.6	1,795.8	2,103.9	2,477.2	2,943.9	3,484.1
Application of Funds	•	•	•	•	•	•	•
Shareholders' inv	50.5	58.6	85.4	152.4	131.3	157.6	189.1
Policyholders' inv	571.2	671.9	905.4	1,083.1	1,464.5	1,659.5	2,037.8
Assets to cover linked liab.	633.8	541.8	747.6	806.2	792.0	966.7	1,058.5
Current assets	40.4	43.1	49.8	52.3	69.8	87.2	109.0
Total	1,300.3	1,321.6	1,795.8	2,103.9	2,477.2	2,943.9	3,484.1
	<u> </u>	<u> </u>	<u> </u>	<u> </u>	<u> </u>	<u> </u>	·
Operating ratios (%)	FY19	FY20	FY21	FY22	FY23	FY24E	FY25E
Investment yield	7.5%	-2.7%	19.8%	10.2%	5.6%	8.6%	8.4%
Commissions / GWP	3.8%	4.6%	4.4%	4.2%	5.0%	4.5%	4.5%
- first year premiums	15.5%	17.9%	18.5%	17.0%	17.9%	19.3%	19.4%
- renewal premiums	1.5%	1.6%	1.5%	1.5%	1.8%	1.5%	1.5%
- single premiums	1.2%	1.3%	1.0%	1.3%	1.6%	0.5%	0.5%
Operating expenses / GWP	13.1%	13.0%	11.9%	12.2%	14.7%	11.3%	11.2%
Total expense ratio	16.9%	17.6%	16.3%	16.4%	19.6%	15.8%	15.7%
Claims / NWP	46.4%	56.4%	57.1%	66.3%	68.5%	55.8%	55.4%
Solvency ratio	188%	184%	201%	176%	203%	266%	268%
Persistency ratios (%)	FY19	FY20	FY21	FY22	FY23	FY24E	FY25E
13th Month	87.2%	90.1%	90.0%	87.5%	87.5%	87.5%	87.5%
25th Month	80.5%	80.2%	81.0%	78.8%	78.7%	78.7%	78.7%
37th Month	72.0%	73.8%	71.0%	67.5%	72.4%	72.4%	72.4%
49th Month	67.7%	67.2%	67.0%	63.2%	64.0%	67.7%	68.5%
61st Month	52.3%	55.0%	53.0%	54.0%	52.3%	53.2%	55.8%
Des (No. 1911) and the section (OC)	EV4.0	EV/20	EV24	EV22	EV22	EVO 4E	FWOFF
Profitability ratios (%)	FY19 24.6%	FY20	FY21	FY22 27.4%	FY23	FY24E 28.5%	FY25E
VNB margin (%) RoE (%)		25.9%	26.1%		27.6% 9.6%		29.4%
Operating ROEV	24.5%	20.8%	17.6% 18.5%	10.0% 16.5%	19.7%	11.9% 19.3%	12.9% 19.5%
RoEV (%)	20.1%	12.9%	28.9%	23.8%	19.7%	19.5%	19.1%
NOEV (78)	20.370	12.970	28.570	23.870	13.570	13.5/6	19.1/0
Valuation & key data	FY19	FY20	FY21	FY22	FY23	FY24E	FY25E
Total AUMs (INR b)	1,256	1,272	1,738	2,042	2,388	2,867	3,384
- of which equity AUMs (%)	38%	29%	36%	37%	30%	39%	40%
Dividend %	16%	0%	0%	17%	19%	23%	26%
Dividend payout ratio (%)	31%	0%	0%	0%	-117%	31%	29%
EPS, INR	6.3	6.4	6.7	5.7	6.3	7.5	8.9
VNB (INR b)	15.40	19.18	21.85	26.74	36.74	42.2	52.7
Embedded Value (INR b)	182.7	206.3	266.2	329.4	395.1	472.3	562.6
EV per share (INR)	84.9	95.8	123.6	153.0	183.5	219.4	261.4
VIF as % of EV	68%	65%	66%	64%	68%	71%	73%
P/VIF (%)	9.2	8.5	6.5	5.4	4.3	3.4	2.8
P/AUM (%)	91%	90%	66%	56%	48%	40%	34%
P/EV (x)	6.3	5.5	4.3	3.5	2.9	2.4	2.0
P/EPS (x)	83.9	82.9	79.0	93.2	84.2	70.8	59.9
P/EVOP (x)	37.4	34.5	29.9	26.0	17.6	15.0	12.4
P/VNB (x)	74.3	59.7	52.4	42.8	31.2	27.1	21.7
-							

Explanation of Investment Rating						
Investment Rating	Expected return (over 12-month)					
BUY	>=15%					
SELL	<-10%					
NEUTRAL	< - 10 % to 15%					
UNDER REVIEW	Rating may undergo a change					
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation					

*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall be within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on www.motilaloswal.com. MOFSL (erstwhile Motilal Oswal Securities Limited - MOSL) is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL),NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products. Details of associate entities of Motifal Oswal Financial Services Limited are available on the website at http://onlinereports.motifaloswal.com/Dormant/documents/List%20of%20Associate%20companies.pdf

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at transactions. Details of pending Enquiry Proculaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx Enquiry Proceedings of Motilal

A graph of daily closing prices of securities is available at www.nseindia.com, www.bseindia.com. Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

For Hong Kong:

Disclosures

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg. No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the 1934 act 1934 act 1934) and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

For Singapore
In Singapore, this report is being distributed by Motilal Oswal Capital Markets Singapore Pte Ltd ("MOCMSPL") (Co. Reg. NO. 201129401Z) which is a holder of a capital markets services license and an exempt financial adviser in Singapore. As per the approved agreement under Paragraph 9 of Third Schedule of Securities and Futures Act (CAP 289) and Paragraph 11 of First Schedule of Financial Advisors Act (CAP 110) provided to MOCMSPL by Monetary Authority of Singapore. Persons in Singapore should contact MOCMSPL in respect of any matter arising from, or in connection with this report/publication/communication. This report is distributed solely to persons who qualify as "Institutional Investors", of which some of whom may consist of "accredited" institutional investors as defined in section 4A(1) of the Securities and Futures Act, Chapter 289 of Singapore ("the SFA"). Accordingly, if a Singapore person is not or ceases to be such an institutional investor, such Singapore Person must immediately discontinue any use of this Report and inform MOCMSPL.

Specific Disclosures

- MOFSL, Research Analyst and/or his relatives does not have financial interest in the subject company, as they do not have equity holdings in the subject company.
- MOFSL, Research Analyst and/or his relatives do not have actual/beneficial ownership of 1% or more securities in the subject company MOFSL, Research Analyst and/or his relatives have not received compensation/other benefits from the subject company in the past 12 months
- MOFSL, Research Analyst and/or his relatives do not have material conflict of interest in the subject company at the time of publication of research report
- Research Analyst has not served as director/officer/employee in the subject company MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months 6
- MOFSL has not received compensation for investment banking/ merchant banking/brokerage services from the subject company in the past 12 months
- MOFSL has not received compensation for other than investment banking/merchant banking/brokerage services from the subject company in the past 12 months 8
- MOFSL has not received any compensation or other benefits from third party in connection with the research report
- MOFSL has not engaged in market making activity for the subject company

The associates of MOFSL may have:

- financial interest in the subject company
- actual/beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public
- received compensation/other benefits from the subject company in the past 12 months
- any other potential conflict of interests with respect to any recommendation and other related information and opinions; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.
- acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or
- act as an advisor or lender/borrower to such company(ies) received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.
- Served subject company as its clients during twelve months preceding the date of distribution of the research report.

The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report

11 27 April 2023

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, it does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263; www.motilaloswal.com.

Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai-400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal, Email Id: na@motilaloswal.com, Contact No::022-40548085.

Grievance Redressal Cell

Official Control Control		
Contact Person	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	query@motilaloswal.com
Ms. Kumud Upadhyay	022 40548082	servicehead@motilaloswal.com
Mr. Aiay Menon	022 40548083	am@motilaloswal.com

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412 . AMFI: ARN .: 146822. IRDA Corporate Agent – CA0579. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products. Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dpgrievances@motilaloswal.com.